Literature DB >> 20971575

Microscopic disease extension in three dimensions for non-small-cell lung cancer: development of a prediction model using pathology-validated positron emission tomography and computed tomography features.

Judith van Loon1, Christian Siedschlag, Joep Stroom, Hans Blauwgeers, Robert-Jan van Suylen, Joost Knegjens, Maddalena Rossi, Angela van Baardwijk, Liesbeth Boersma, Houke Klomp, Wouter Vogel, Sjaak Burgers, Kenneth Gilhuijs.   

Abstract

PURPOSE: One major uncertainty in radiotherapy planning of non-small-cell lung cancer concerns the definition of the clinical target volume (CTV), meant to cover potential microscopic disease extension (MDE) around the macroscopically visible tumor. The primary aim of this study was to establish pretreatment risk factors for the presence of MDE. The secondary aim was to establish the impact of these factors on the accuracy of positron emission tomography (PET) and computed tomography (CT) to assess the total tumor-bearing region at pathologic examination (CTV(path)). METHODS AND MATERIALS: 34 patients with non-small-cell lung cancer who underwent CT and PET before lobectomy were included. Specimens were examined microscopically for MDE. The gross tumor volume (GTV) on CT and PET (GTV(CT) and GTV(PET), respectively) was compared with the GTV and the CTV at pathologic examination, tissue deformations being taken into account. Using multivariate logistic regression, image-based risk factors for the presence of MDE were identified, and a prediction model was developed based on these factors.
RESULTS: MDE was found in 17 of 34 patients (50%). The MDE did not exceed 26 mm in 90% of patients. In multivariate analysis, two parameters (mean CT tumor density and GTV(CT)) were significantly associated with MDE. The area under the curve of the two-parameter prediction model was 0.86. Thirteen tumors (38%, 95% CI: 24-55%) were identified as low risk for MDE, being potential candidates for reduced-intensity therapy around the GTV. In the low-risk group, the effective diameter of the GTV(CT/PET) accurately represented the CTV(path). In the high-risk group, GTV(CT/PET) underestimated the CTV(path) with, on average, 19.2 and 26.7 mm, respectively.
CONCLUSIONS: CT features have potential to predict the presence of MDE. Tumors identified as low risk of MDE show lower rates of disease around the GTV than do high-risk tumors. Both CT and PET accurately visualize the CTV(path) in low-risk tumors but underestimate it in high-risk tumors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20971575     DOI: 10.1016/j.ijrobp.2010.09.001

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

1.  Is spread through alveolar spaces, the newly recognized pattern of invasion, a potential game changer in lung adenocarcinoma?

Authors:  Sarina Bains; Prasad S Adusumilli
Journal:  Ann Transl Med       Date:  2015-12

Review 2.  Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities.

Authors:  Wouter van Elmpt; Catharina M L Zegers; Marco Das; Dirk De Ruysscher
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

3.  Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211.

Authors:  Mathieu Hatt; John A Lee; Charles R Schmidtlein; Issam El Naqa; Curtis Caldwell; Elisabetta De Bernardi; Wei Lu; Shiva Das; Xavier Geets; Vincent Gregoire; Robert Jeraj; Michael P MacManus; Osama R Mawlawi; Ursula Nestle; Andrei B Pugachev; Heiko Schöder; Tony Shepherd; Emiliano Spezi; Dimitris Visvikis; Habib Zaidi; Assen S Kirov
Journal:  Med Phys       Date:  2017-05-18       Impact factor: 4.071

4.  Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Camelia S Sima; Hideki Ujiie; Nabil P Rizk; David R Jones; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

5.  Pulmonary metastectomy: impact of tumor histology and size.

Authors:  Michal J Lada; Michael T Milano; Carolyn E Jones
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

6.  Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy.

Authors:  Jonathan E Leeman; Andreas Rimner; Joseph Montecalvo; Meier Hsu; Zhigang Zhang; Donata von Reibnitz; Kelly Panchoo; Ellen Yorke; Prasad S Adusumilli; William Travis; Abraham J Wu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-09-29       Impact factor: 7.038

Review 7.  The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer.

Authors:  Tom Konert; Jeroen B van de Kamer; Jan-Jakob Sonke; Wouter V Vogel
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

8.  Impact of dose to lung outside the planning target volume on distant metastasis or progression after SBRT for early-stage non-small cell lung cancer.

Authors:  Ryan T Hughes; Cole R Steber; Travis J Jacobson; Michael K Farris
Journal:  Radiother Oncol       Date:  2021-03-09       Impact factor: 6.280

9.  Radiotherapy Planning and Molecular Imaging in Lung Cancer.

Authors:  Angelina Filice; Massimiliano Casali; Patrizia Ciammella; Marco Galaverni; Federica Fioroni; Cinzia Iotti; Annibale Versari
Journal:  Curr Radiopharm       Date:  2020

10.  Optimal Standardized Uptake Value Threshold for Auto contouring of Gross Tumor Volume using Positron Emission Tomography/Computed Tomography in Patients with Operable Nonsmall-Cell Lung Cancer: Comparison with Pathological Tumor Size.

Authors:  Anil Tibdewal; Mangesh Patil; Shagun Misra; Nilendu Purandare; Venkatesh Rangarajan; Naveen Mummudi; George Karimundackal; Sabita Jiwnani; Jaiprakash Agarwal
Journal:  Indian J Nucl Med       Date:  2021-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.